The November issue of Transplantation Direct is ready for viewing. This issue includes reports on multiple topics, including articles in kidney transplantation relating to the use of sodium-glucose cotransporter 2 inhibitors in diabetic recipients, absolute versus relative ddcfDNA measurements to detect rejection, factors influencing de novo thrombotic microangiopathy in early transplant loss, and the use of belatacept in liver transplant recipients receiving a subsequent kidney transplant; experimentally, we have a report on delivery of renal organoids in pigs. Another article reports on pushing the age envelop in cases of simultaneous pancreas-kidney transplantation. In liver transplantation, for patients who do not accept blood transfusions, there is a case report on safely doing a transfusion-free re-transplant for post-transplant hepatic artery thrombosis. In the bone marrow transplant arena, predictive factors influencing immune reconstitution are examined after hematopoietic stem cell transplantation for leukemia. Organ donation is also featured, with a new model of informed consent for non-standard risk donors, and a report on factors associated with early graft loss in expanded criteria kidney transplants. On the topic of infectious diseases, the National COVID Cohort Collaborative (N3C) reports on factors related to COVID-19 diagnostics and outcomes; we also have a report on mechanistic investigations as to how CMV immunoglobulin prophylaxis prevents infections post-transplantation. All these articles, and more, are available via open access publishing at the Transplantation Direct website.
The TTS-ILTS Paired Transplant Centers Program is a collaboration between The Transplantation Society (TTS) and the International Liver Transplantation Society (ILTS) supporting new liver transplant programs in emerging economies.
Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease.
A meta-analysis of 32 studies documented that the immunogenicity rate among patients receiving dialysis was 41% after the first dose and 89% after the second dose. Diabetes might be a risk factor for nonresponse in the dialysis population. Patients receiving dialysis had a lower antibody response rate than did individuals not receiving dialysis, particularly after the first dose.
Adults receiving dialysis have a higher mortality risk when infected with SARS-CoV-2 than do adults not receiving dialysis.1,2 Because most clinical trials have not included people with end-stage kidney disease (ESKD),3,4 immunogenicity rates are instead assessed to determine the efficacy of SARS-CoV-2 vaccines in this population. Several studies have reported that antibody response rates vary depending on vaccination protocols, vaccine types, and populations. Old age or use of immunosuppression medication have been identified as risk factors for vaccine nonresponse.5-8 However, the immunogenicity rates of patients receiving dialysis have not yet been systematically reviewed, to our knowledge.
In this study, immunogenicity rates among people with ESKD after receiving SARS-CoV-2 vaccines were investigated, as were potential risk factors for vaccine nonresponse and significant differences in antibody response rates between adults receiving dialysis and those not receiving dialysis
Trials of the Pfizer-BioNTech BNT162b2 mRNA vaccine showed 95% efficacy in preventing symptomatic disease; however, the trials excluded immunocompromised patients (ICPs). We aim at analyzing antibody response in ICPs.